Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR070803 in advanced colorectal cancer
NCT05945901Phase 3Active, not recruiting
- Sponsor
- Hengrui
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) comparing HR070803 with Placebo (2 arms). Primary endpoints: Adverse Events According to NCI-CTCAE v5.0 at 48 months, Serious Adverse Events at 48 months and 1 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
CPO-120
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05945901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05945901.